Related Experiment Video
Updated: Dec 28, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas
Tejus A Bale1, Jamal Benhamida2, Sudarshana Roychoudury2
1Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. balet@mskcc.org.
Abstract:
We describe a morphologically distinct pattern of tumor infarction and associated sarcoma-like changes, mimicking focal anaplasia, in otherwise WHO grade I meningiomas. The described cases (n = 9) all demonstrated a discrete spindle-cell (pseudosarcomatous) component with brisk mitotic activity (12-14 mitoses/10 HPF), elevated Ki-67 (mean 75.5 ± 25.0%, quantified), absence of PR, SSTR2A, or EMA expression, and potential SMA expression (50%). Despite these high-grade features, all nine patients remained free of progression or recurrence post resection (follow-up mean: 49.8 months). In contrast, among a comparison (control) cohort of consecutive WHO grade II and III meningiomas (n = 16), as expected, progression rate was high (68.8%, P = 0.002, Fisher's exact, average time to progression = 25 months, follow-up mean: 39.8 months). While necrosis was a frequent feature among atypical/anaplastic meningiomas (12/16, 75%), and elevated mitoses and proliferative index were present consistent with histologic grade, a well-defined zonal pattern with pseudosarcomatous component was not present among these tumors. DNA methylation-based analysis readily distinguished meningiomas by copy number profiles and DNA-based methylation meningioma random forest classification analysis (meningioma v2.4 classifier developed at University of Heidelberg); all pseudosarcomatous cases analyzed (4/9) matched with high level calibrated classifier score to "MC benign-1", with isolated loss of chromosome 22q identified as the sole copy number alteration. In contrast, multiple chromosomal losses were detected among the comparison cohort and classifier results demonstrated good concordance with histologic grade. Our findings suggest that pseudosarcomatous alterations represent reactive changes to central meningioma infarction, rather than focal anaplasia, and further support the use of DNA methylation-based analysis as a useful adjunct for predicting meningioma behavior. These indolent tumors should be distinguished from their atypical and anaplastic counterparts.
Insights
Pseudosarcomatous changes in WHO grade I meningiomas are reactive to tumor infarction, not anaplasia. These indolent tumors show no recurrence, unlike higher-grade meningiomas, and are identifiable via DNA methylation analysis.
Area of Science:
- Neuropathology
- Oncology
- Molecular Diagnostics
Background:
- WHO grade I meningiomas are typically benign tumors.
- Tumor infarction can occur in meningiomas, potentially mimicking higher-grade features.
- Distinguishing reactive changes from true anaplasia is crucial for accurate prognosis.
Purpose of the Study:
- To characterize a distinct pattern of tumor infarction and sarcoma-like changes in WHO grade I meningiomas.
- To differentiate these pseudosarcomatous changes from actual anaplastic features.
- To evaluate the utility of DNA methylation profiling in classifying these meningiomas.
Main Methods:
- Histopathological analysis of 9 WHO grade I meningiomas with pseudosarcomatous changes.
- Comparison with 16 WHO grade II and III meningiomas.
- Immunohistochemistry for PR, SSTR2A, EMA, and SMA.
- DNA methylation-based analysis using the meningioma v2.4 classifier.
Main Results:
- WHO grade I meningiomas with infarction showed a pseudosarcomatous component, brisk mitotic activity, and high Ki-67, but no recurrence.
- Higher-grade meningiomas (WHO II/III) exhibited high progression rates and multiple chromosomal losses.
- DNA methylation analysis classified pseudosarcomatous cases as "MC benign-1" with isolated 22q loss, distinct from higher-grade tumors.
Conclusions:
- Pseudosarcomatous changes in meningiomas are likely reactive to infarction, not indicative of anaplasia.
- These specific WHO grade I meningiomas are indolent and should be distinguished from aggressive subtypes.
- DNA methylation profiling is a valuable tool for accurate meningioma classification and behavior prediction.

